AEMD

Business Context and Reporting Period

Company: Aethlon Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010
Business Stage: Development Stage Medical Device Company
Core Technology: Hemopurifier(R) platform designed to reduce infectious viruses and toxins from human blood. The company is focused on clinical trials for HIV, Hepatitis-C, and potential biological warfare agents. No commercial revenue has been generated from the Hemopurifier(R).

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended Dec 31, 2010, was $8.1 million, compared to $3.2 million in the prior year period. This increase was driven by higher operating expenses and significant non-cash charges.
• Operating Expenses: Increased by 65% ($1.4 million) year-over-year for the nine-month period, primarily due to a $1.4 million increase in payroll and related expenses (largely non-cash stock-based compensation) and increased professional fees.
• Debt Extinguishment: The company recorded a total loss on extinguishment of debt of $3.2 million for the nine-month period. This includes a $2.2 million charge in June 2010 related to the restructuring of Series A Convertible Notes and a $963,000 charge in November 2010 related to a settlement with Gemini Master Fund, Ltd.
• Derivative Liabilities: The balance of derivative liabilities increased significantly from $1.05 million at March 31, 2010, to $5.94 million at December 31, 2010, due to the fair value of embedded conversion features and warrants in new and restructured debt instruments.
• Liquidity: Cash increased from $67,950 at the beginning of the period to $234,240, funded primarily by financing activities (issuance of convertible notes and common stock).

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that the company's financial condition raises significant doubt about its ability to continue as a going concern. The company has negative working capital of approximately $9.4 million and an accumulated deficit of over $50 million.
• Capital Needs: Management states that current resources are insufficient to fund operations for the fiscal year ending March 31, 2011. The company estimates a minimum cash burn of $180,000 per month and is actively seeking additional debt or equity financing.
• Unusual Items:
  • Debt Settlements: Significant non-cash losses were recorded due to debt restructuring and settlements, including the Gemini Master Fund settlement which involved exchanging warrants and modifying conversion terms.
  • Derivative Valuation: The company changed its valuation model for warrants from Black-Scholes to a Binomial Lattice model, accounting for this as a change in estimate.
  • Stock-Based Compensation: A significant portion of operating expenses ($1.55 million for the nine months) was non-cash stock-based compensation, including option modifications and vesting of restricted stock.
• Risks:
  • Regulatory Approval: Commercialization depends on FDA approval for clinical trials and eventual marketing clearance, which is uncertain and could take years.
  • Debt Defaults: As of December 31, 2010, approximately $1.5 million in principal of promissory and convertible notes were past due and in default.
  • Liquidated Damages: The company has accrued $680,000 in potential liquidated damages related to registration payment arrangements, with estimates of $36,000 per month accruing until a registration statement is effective.

Investor Verification Checklist

• Capital Raising Status: Verify if the company has successfully secured the additional debt or equity financing required to meet its estimated $180,000 monthly burn rate.
• Debt Restructuring: Confirm the status of the $1.5 million in past-due notes and whether further defaults or settlements are imminent.
• Derivative Liability Volatility: Monitor the fair value of the $5.9 million derivative liability, as fluctuations in the company's stock price will directly impact reported net income/loss.
• Clinical Trial Progress: Verify the status of the Hepatitis-C clinical trial in India and the FDA Investigational Device Exemption (IDE) application for U.S. trials.
• Registration Statement: Check if the company has filed an effective registration statement to stop the accrual of liquidated damages ($36,000/month).